

Christian Hartinger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2301430/christian-hartinger-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243
papers

15,106
citations

68
h-index

117
g-index

265
ext. papers

16,245
ext. citations

5.6
avg, IF

6.66
L-index

#	Paper	IF	Citations
243	Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding.. <i>Angewandte Chemie - International Edition</i> , 2022 , e202201700	16.4	5
242	Substitution of the chlorido ligand for PPh ₃ in anticancer organoruthenium complexes of sulfonamide-functionalized pyridine-2-carbothioamides leads to high cytotoxic activity. <i>Inorganica Chimica Acta</i> , 2022 , 536, 120889	2.7	0
241	Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand.. <i>Frontiers in Chemistry</i> , 2021 , 9, 786367	5	0
240	Incorporation of β -Alanine in Cu(II) ATCUN Peptide Complexes Increases ROS Levels, DNA Cleavage and Antiproliferative Activity*. <i>Chemistry - A European Journal</i> , 2021 , 27, 18093	4.8	1
239	Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	4
238	Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. <i>Inorganica Chimica Acta</i> , 2021 , 518, 120220	2.7	2
237	Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands. <i>Coordination Chemistry Reviews</i> , 2021 , 436, 213849	23.2	10
236	Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2. <i>ChemBioChem</i> , 2021 , 22, 2521-2525, 8	3.8	2
235	Heptadentate, Octadentate, Or Even Nonadentate? Denticity in the Unexpected Formation of an All-Carbon Donor-Atom Ligand in Rh(Cp*)(Anthracenyl-NHC) Complexes. <i>Inorganic Chemistry</i> , 2021 , 60, 8734-8741	5.1	4
234	Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent in vivo activity through an ROS-dependent mechanism. <i>Metallomics</i> , 2021 , 13,	4.5	1
233	Cavity-Containing [FeL] Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity. <i>Frontiers in Chemistry</i> , 2021 , 9, 697684	5	2
232	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. <i>Angewandte Chemie</i> , 2021 , 133, 20081-20085	3.6	0
231	Triazolyl-Functionalized N-Heterocyclic Carbene Half-Sandwich Compounds: Coordination Mode, Reactivity and in vitro Anticancer Activity. <i>ChemMedChem</i> , 2021 , 16, 3017-3026	3.7	3
230	Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. <i>Coordination Chemistry Reviews</i> , 2021 , 439, 213890	23.2	17
229	Tracing the anticancer compound [Ru(η^5 -cymene)(8-oxyquinolinato)Cl] in a biological environment by mass spectrometric methods. <i>Analytical Methods</i> , 2021 , 13, 1463-1469	3.2	2
228	High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes. <i>Biomedicines</i> , 2021 , 9,	4.8	2
227	Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide. <i>Molecules</i> , 2021 , 26,	4.8	2

226	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. <i>Angewandte Chemie - International Edition</i> , 2021 , 60, 19928-19932	16.4	10
225	Anthracenyl Functionalization of Half-Sandwich Carbene Complexes: Anticancer Activity and Reactions with Biomolecules. <i>Inorganic Chemistry</i> , 2021 , 60, 14636-14644	5.1	7
224	Determination of Relative Stabilities of Metal-Peptide Bonds in the Gas Phase. <i>Chemistry - A European Journal</i> , 2021 , 27, 16401-16406	4.8	
223	Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. <i>Coordination Chemistry Reviews</i> , 2021 , 445, 213950	23.2	12
222	In-flow SAXS investigation of whey protein isolate hydrolyzed by bromelain. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2021 , 631, 127662	5.1	0
221	Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
220	Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination. <i>Inorganic Chemistry</i> , 2021 , 60, 2414-2424	5.1	8
219	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2020 , 59, 14609-14614	16.4	12
218	A Reduced-Symmetry Heterobimetallic [PdPtL ₄] ⁴⁺ Cage: Assembly, Guest Binding, and Stimulus-Induced Switching. <i>Angewandte Chemie</i> , 2020 , 132, 11194-11200	3.6	17
217	A Reduced-Symmetry Heterobimetallic [PdPtL] Cage: Assembly, Guest Binding, and Stimulus-Induced Switching. <i>Angewandte Chemie - International Edition</i> , 2020 , 59, 11101-11107	16.4	46
216	Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl Complexes. <i>Inorganic Chemistry</i> , 2020 , 59, 3281-3289	5.1	28
215	From the hypothesis-driven development of organometallic anticancer drugs to new methods in mode of action studies. <i>Advances in Inorganic Chemistry</i> , 2020 , 75, 339-359	2.1	2
214	Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs. <i>Metallomics</i> , 2020 , 12, 1627-1636	4.5	8
213	Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands. <i>Inorganic Chemistry</i> , 2020 , 59, 14879-14890	5.1	6
212	A Combined Spectroscopic and Protein Crystallography Study Reveals Protein Interactions of Rh(NHC) Complexes at the Molecular Level. <i>Inorganic Chemistry</i> , 2020 , 59, 17191-17199	5.1	12
211	Thiourea-Derived Chelating Ligands and Their Organometallic Compounds: Investigations into Their Anticancer Activity. <i>Molecules</i> , 2020 , 25,	4.8	5
210	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie</i> , 2020 , 132, 14717-14722	3.6	2
209	Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity. <i>Chemical Communications</i> , 2019 , 55, 12016-12019	5.8	27

208	Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties. <i>Chemistry - an Asian Journal</i> , 2019 , 14, 1262-1270	4.5	12
207	Gel electrophoresis in combination with laser ablation-inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin. <i>Electrophoresis</i> , 2019 , 40, 2329-2335	3.6	4
206	Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones. <i>Polyhedron</i> , 2019 , 172, 141-147	2.7	2
205	Design of organoruthenium complexes for nanoparticle functionalization. <i>Journal of Organometallic Chemistry</i> , 2019 , 891, 64-71	2.3	
204	Medicinal Chemistry 2019 , 157-172		3
203	Hydroxyquinoline-derived anticancer organometallics: Introduction of amphiphilic PTA as an ancillary ligand increases their aqueous solubility. <i>Journal of Inorganic Biochemistry</i> , 2019 , 199, 110768	4.2	21
202	Chemical imaging and assessment of cadmium distribution in the human body. <i>Metallomics</i> , 2019 , 11, 2010-2019	4.5	32
201	Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds. <i>Organometallics</i> , 2019 , 38, 361-374	3.8	21
200	Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation. <i>Metallomics</i> , 2018 , 10, 455-462	4.5	11
199	Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct. <i>Chemical Communications</i> , 2018 , 54, 6120-6123	5.8	26
198	Medicinal Chemistry of Gold Anticancer Metallodrugs. <i>Metal Ions in Life Sciences</i> , 2018 , 18,	2.6	8
197	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. <i>Inorganic Chemistry</i> , 2018 , 57, 2851-2864	5.1	28
196	Antitumor Metallodrugs that Target Proteins. <i>Metal Ions in Life Sciences</i> , 2018 , 18,	2.6	4
195	Anticancer metallodrugs: where is the next cisplatin?. <i>Future Medicinal Chemistry</i> , 2018 , 10, 615-617	4.1	85
194	Analysis of ruthenium anticancer agents by MEEKC-UV and MEEKC-ICP-MS: Impact of structural motifs on lipophilicity and biological activity. <i>Electrophoresis</i> , 2018 , 39, 1201-1207	3.6	13
193	Quinoline-para-quinones and metals: coordination-assisted formation of quinoline-ortho-quinones. <i>Chemical Communications</i> , 2018 , 54, 992-995	5.8	11
192	Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel l-phenylalanine-derived arene ligand on the biological activity. <i>Dalton Transactions</i> , 2018 , 47, 2192-2201	4.3	28
191	Advanced metallomics methods in anticancer metallodrug mode of action studies. <i>TrAC - Trends in Analytical Chemistry</i> , 2018 , 104, 110-117	14.6	17

190	A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action. <i>Inorganic Chemistry</i> , 2018 , 57, 8521-8529	5.1	18
189	Understanding the interactions of diruthenium anticancer agents with amino acids. <i>Journal of Biological Inorganic Chemistry</i> , 2018 , 23, 1159-1164	3.7	7
188	(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules. <i>Organometallics</i> , 2018 , 37, 1575-1584	3.8	30
187	Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. <i>Chemical Society Reviews</i> , 2018 , 47, 909-928	58.5	245
186	Organometallics in Cancer Treatment Non-conventional Structures and Modes of Action 2018 ,		
185	From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. <i>Inorganic Chemistry</i> , 2018 , 57, 14427-14434	5.1	38
184	Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes. <i>European Journal of Medicinal Chemistry</i> , 2018 , 159, 282-291	6.8	7
183	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MS. <i>Monatshefte Für Chemie</i> , 2018 , 149, 1719-1726	1.4	15
182	Organoruthenium and Organoosmium Complexes of 2-Pyridinecarbothioamides Functionalized with a Sulfonamide Motif: Synthesis, Cytotoxicity and Biomolecule Interactions. <i>ChemPlusChem</i> , 2018 , 83, 612-619	2.8	9
181	Hyphenation of capillary electrophoresis to inductively coupled plasma mass spectrometry with a modified coaxial sheath-flow interface. <i>Journal of Chromatography A</i> , 2018 , 1561, 76-82	4.5	5
180	Cobalt complexes as internal standards for capillary zone electrophoresis-mass spectrometry studies in biological inorganic chemistry. <i>Journal of Biological Inorganic Chemistry</i> , 2017 , 22, 789-798	3.7	4
179	Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity. <i>Journal of Organometallic Chemistry</i> , 2017 , 839, 31-37	2.3	17
178	Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. <i>Chemistry - A European Journal</i> , 2017 , 23, 4893-4902	4.8	29
177	Ruthenium Anticancer Agents From Cisplatin Analogues to Rational Drug Design 2017 , 1-21		2
176	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. <i>Angewandte Chemie - International Edition</i> , 2017 , 56, 8267-8271	16.4	71
175	Functionalization of Ruthenium(II)([p-cymene](3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. <i>ChemPlusChem</i> , 2017 , 82, 841-847	2.8	12
174	The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography. <i>Chemical Communications</i> , 2017 , 53, 4246-4249	5.8	31
173	Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives. <i>ChemMedChem</i> , 2017 , 12, 1882-1892	3.7	11

172	Anticancer Ru(η -p-cymene) complexes of 2-pyridinecarbothioamides: A structure-activity relationship study. <i>Journal of Inorganic Biochemistry</i> , 2017 , 177, 395-401	4.2	21
171	Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. <i>Journal of Inorganic Biochemistry</i> , 2017 , 177, 322-327	4.2	24
170	Innenrücktitelbild: Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin (Angew. Chem. 28/2017). <i>Angewandte Chemie</i> , 2017 , 129, 8415-8415	3.6	
169	Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin. <i>Angewandte Chemie</i> , 2017 , 129, 8379-8383	3.6	11
168	Ruthenium Anticancer Agents En Route to the Tumor 2017 , 161-180		
167	DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metaldrug binding selectivity. <i>Chemical Communications</i> , 2017 , 53, 8002-8005	5.8	21
166	Cationic Ru(η -p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones with Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents. <i>European Journal of Inorganic Chemistry</i> , 2017 , 2017, 1721-1727	2.3	22
165	Reprint of: Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2017 , 454, 247-253	2.7	2
164	The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions 2017 , 355-386		
163	The development of RAPTA compounds for the treatment of tumors. <i>Coordination Chemistry Reviews</i> , 2016 , 306, 86-114	23.2	320
162	Flavonoid-Based Organometallics with Different Metal Centers – Investigations of the Effects on Reactivity and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2016 , 2016, 240-246	2.3	19
161	Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand. <i>Journal of Inorganic Biochemistry</i> , 2016 , 165, 100-107	4.2	31
160	Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. <i>Journal of Inorganic Biochemistry</i> , 2016 , 160, 250-5	4.2	72
159	Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity. <i>Inorganica Chimica Acta</i> , 2016 , 443, 179-185	2.7	33
158	Ru(η -p-cymene) Complexes of Bioactive 1,2-Benzothiazines: Protein Binding vs. Antitumor Activity. <i>European Journal of Inorganic Chemistry</i> , 2016 , 2016, 1376-1382	2.3	17
157	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. <i>Electrophoresis</i> , 2016 , 37, 959-72	3.6	19
156	Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2016 , 450, 124-130	2.7	12
155	Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems. <i>Dalton Transactions</i> , 2016 , 45, 13091-103	4.3	38

154	Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes. <i>Chemistry - A European Journal</i> , 2016 , 22, 11413-21	4.8	18
153	Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells. <i>Chemistry - A European Journal</i> , 2015 , 21, 5110-7	4.8	49
152	Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). <i>Metallomics</i> , 2015 , 7, 508-15	4.5	25
151	Target profiling of an antimetastatic RAPTAs agent by chemical proteomics: relevance to the mode of action. <i>Chemical Science</i> , 2015 , 6, 2449-2456	9.4	105
150	Capillary electrophoresis in metallodrug development. <i>Drug Discovery Today: Technologies</i> , 2015 , 16, 16-22	7.1	8
149	The rearrangement of tosylated flavones to 1?-(alkylamino)aurones with primary amines. <i>Tetrahedron</i> , 2015 , 71, 8953-8959	2.4	8
148	Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents. <i>Organometallics</i> , 2015 , 34, 5658-5668	3.8	102
147	Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTAs complexes and their anticancer activity. <i>Dalton Transactions</i> , 2015 , 44, 3614-23	4.3	63
146	Expanding on the Structural Diversity of Flavone- Derived Ruthenium(II)(β -arene) Anticancer Agents 2015 , 1,		12
145	Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity. <i>ChemPlusChem</i> , 2015 , 80, 231-236	2.8	27
144	Physicochemical studies on the copper(II) binding by glycosylated collagen telopeptides. <i>Organic and Biomolecular Chemistry</i> , 2015 , 13, 3058-63	3.9	10
143	Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. <i>ChemMedChem</i> , 2014 , 9, 1351-5	3.7	11
142	Opening the lid on piano-stool complexes: An account of π -ruthenium(II) β -arene complexes with medicinal applications. <i>Journal of Organometallic Chemistry</i> , 2014 , 751, 251-260	2.3	206
141	Anticancer Ruthenium(β -p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. <i>Organometallics</i> , 2014 , 33, 5546-5553	3.8	72
140	Development of anticancer agents: wizardry with osmium. <i>Drug Discovery Today</i> , 2014 , 19, 1640-8	8.8	113
139	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2014 , 134, 57-65	4.2	64
138	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. <i>Dalton Transactions</i> , 2014 , 43, 9851-5	4.3	7
137	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. <i>Metallomics</i> , 2014 , 6, 1616-25	4.5	52

136	Ruthenium(II)(β -arene) complexes of thiourea derivatives: synthesis, characterization and urease inhibition. <i>Molecules</i> , 2014 , 19, 8080-92	4.8	21
135	Solution equilibrium studies of anticancer ruthenium(II)- β -p-cymene complexes of pyridinecarboxylic acids. <i>Polyhedron</i> , 2014 , 67, 51-58	2.7	12
134	A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP). <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 6417-24	4.4	13
133	Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 1791-808	4.4	55
132	Solution equilibria of anticancer ruthenium(II)-(β -p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2013 , 127, 161-8	4.2	19
131	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2013 , 18, 249-60	3.7	14
130	Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. <i>Journal of Biological Inorganic Chemistry</i> , 2013 , 18, 9-17	3.7	104
129	Rhodium(Cp*) Compounds with Flavone-derived Ligand Systems: Synthesis and Characterization. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2013 , 639, 1648-1654	1.3	15
128	Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. <i>Chemistry - A European Journal</i> , 2013 , 19, 9297-307	4.8	48
127	A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin. <i>Journal of Inorganic Biochemistry</i> , 2013 , 119, 38-42	4.2	31
126	Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. <i>Chemical Science</i> , 2013 , 4, 1837	9.4	95
125	Solution equilibrium studies on anticancer ruthenium(II)- β -p-cymene complexes of 3-hydroxy-2(1H)-pyridones. <i>Journal of Organometallic Chemistry</i> , 2013 , 734, 38-44	2.3	19
124	DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells. <i>Nanotoxicology</i> , 2013 , 7, 2-20	5.3	21
123	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. <i>Dalton Transactions</i> , 2013 , 42, 6193-202	4.3	71
122	Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. <i>Chemical Society Reviews</i> , 2013 , 42, 6186-99	58.5	115
121	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. <i>Chemical Communications</i> , 2013 , 49, 3348-50	5.8	116
120	Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. <i>Chemistry - A European Journal</i> , 2013 , 19, 4308-18	4.8	29
119	Influence of the β -coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. <i>Frontiers in Chemistry</i> , 2013 , 1, 27	5	16

118	Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. <i>Journal of Inorganic Biochemistry</i> , 2012 , 108, 91-5	4.2	49
117	Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites. <i>Analytical and Bioanalytical Chemistry</i> , 2012 , 402, 2655-62	4.4	38
116	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. <i>Journal of Biological Inorganic Chemistry</i> , 2012 , 17, 465-74	3.7	49
115	Capillary zone electrophoresis and capillary zone electrophoresis-electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutions. <i>Journal of Chromatography A</i> , 2012 , 1267, 156-61	4.5	15
114	Challenges and Opportunities in the Development of Organometallic Anticancer Drugs. <i>Organometallics</i> , 2012 , 31, 5677-5685	3.8	454
113	Organometallic ruthenium and osmium compounds of pyridin-2- and -4-ones as potential anticancer agents. <i>Chemistry and Biodiversity</i> , 2012 , 9, 1718-27	2.5	16
112	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. <i>Chemical Communications</i> , 2012 , 48, 4839-41	5.8	125
111	Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. <i>Journal of Inorganic Biochemistry</i> , 2012 , 117, 189-97	4.2	43
110	Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex. <i>Organometallics</i> , 2012 , 31, 5867-5874	3.8	53
109	Structure-activity relationships of targeted Ru(II)(β -p-cymene) anticancer complexes with flavonol-derived ligands. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 10512-22	8.3	119
108	Anticancer activity of methyl-substituted oxaliplatin analogs. <i>Molecular Pharmacology</i> , 2012 , 81, 719-28	4.3	39
107	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. <i>Chemical Communications</i> , 2012 , 48, 1475-7	5.8	82
106	Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications. <i>Electrophoresis</i> , 2012 , 33, 622-34	3.6	21
105	Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. <i>Inorganic Chemistry</i> , 2012 , 51, 3633-9	5.1	46
104	Synthesis of [Ru(II)(β -p-cymene)(PPh ₃)(L)Cl]PF ₆ complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands. <i>Inorganica Chimica Acta</i> , 2012 , 380, 211-215	2.7	10
103	Physicochemical Studies and Anticancer Potency of Ruthenium β -p-Cymene Complexes Containing Antibacterial Quinolones. <i>Organometallics</i> , 2011 , 30, 2506-2512	3.8	101
102	Ruthenium and Other Non-Platinum Anticancer Compounds 2011 , 151-174		39
101	LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. <i>Metallomics</i> , 2011 , 3, 1049-55	4.5	58

100	Anticancer activity of metal complexes: involvement of redox processes. <i>Antioxidants and Redox Signaling</i> , 2011 , 15, 1085-127	8.4	352
99	Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations. <i>Archives of Toxicology</i> , 2011 , 85, 799-812	5.8	104
98	Letters to a Young Chemist. Herausgegeben von Abhik Ghosh.. <i>Angewandte Chemie</i> , 2011 , 123, 12604-12605	3.6	60
97	A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. <i>Chemistry - A European Journal</i> , 2011 , 17, 3562-6	4.8	149
96	Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 4202-10	3.4	20
95	Pyrone derivatives and metals: From natural products to metal-based drugs. <i>Journal of Organometallic Chemistry</i> , 2011 , 696, 999-1010	2.3	77
94	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. <i>Journal of Inorganic Biochemistry</i> , 2011 , 105, 46-51	4.2	94
93	From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. <i>Journal of Inorganic Biochemistry</i> , 2011 , 105, 224-31	4.2	63
92	Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 2688-702	3	76
91	Organometallic Antitumour Agents with Alternative Modes of Action. <i>Topics in Organometallic Chemistry</i> , 2010 , 57-80	0.6	55
90	Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?. <i>Inorganic Chemistry</i> , 2010 , 49, 7953-63	5.1	98
89	{{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 7356-64	8.3	43
88	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)(β -Arene) Complexes. <i>Australian Journal of Chemistry</i> , 2010 , 63, 1521	1.2	30
87	Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticle catalyst reservoirs. <i>Physical Chemistry Chemical Physics</i> , 2010 , 12, 1834-41	3.6	54
86	Osmium(II)-versus ruthenium(II)-arene carbohydrate-based anticancer compounds: similarities and differences. <i>Dalton Transactions</i> , 2010 , 39, 7345-52	4.3	81
85	Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. <i>Journal of Biological Inorganic Chemistry</i> , 2010 , 15, 677-88	3.7	75
84	Metabolization of [Ru(eta(6)-C(6)H(5)CF(3))(pta)Cl(2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. <i>Journal of Biological Inorganic Chemistry</i> , 2010 , 15, 919-27	3.7	43
83	Synthesis, cytotoxicity, and COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin derivatives against human cancer cells. <i>ChemMedChem</i> , 2010 , 5, 2039-50	3.7	68

82	The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. <i>Electrophoresis</i> , 2010 , 31, 1144-50	3.6	44
81	An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts. <i>Chemistry - A European Journal</i> , 2010 , 16, 6473-81	4.8	18
80	Isolierung instabiler Benzochinonanaloga durch Koordination an ein [(β -C5Me5)Ir]-Fragment und tumorhemmende Aktivität der resultierenden Komplexe. <i>Angewandte Chemie</i> , 2010 , 122, 8482-8483	3.6	2
79	Trapping unstable benzoquinone analogues by coordination to a [(η -C(5)Me(5))Ir] fragment and the anticancer activity of the resulting complexes. <i>Angewandte Chemie - International Edition</i> , 2010 , 49, 8304-5	16.4	15
78	Mannich products of kojic acid and N-heterocycles and their Ru(II) π -arene complexes: Synthesis, characterization and stability. <i>Journal of Organometallic Chemistry</i> , 2010 , 695, 875-881	2.3	24
77	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(η -cymene)(PPH2(o-C6H4O)- η -P,O)(pta)] ⁺ and an investigation of its cytotoxic effects. <i>Comptes Rendus Chimie</i> , 2010 , 13, 1144-1150	2.7	12
76	DNA interactions of dinuclear Ru(II) arene antitumor complexes in cell-free media. <i>Biochemical Pharmacology</i> , 2009 , 77, 364-74	6	74
75	Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. <i>Chemistry - A European Journal</i> , 2009 , 15, 12283-91	4.8	102
74	New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10-phenanthroline)tris(thiocyanato- κ -N)lanthanum(III) (KP772) and Its Interaction with Biomolecules. <i>European Journal of Inorganic Chemistry</i> , 2009 , 2009, 4282-4287	2.3	30
73	The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. <i>Electrophoresis</i> , 2009 , 30, 2720-7	3.6	43
72	Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS. <i>Electrophoresis</i> , 2009 , 30, 4075-82	3.6	23
71	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. <i>Journal of Organometallic Chemistry</i> , 2009 , 694, 922-929	2.3	58
70	A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 3388-93	3.4	10
69	Bioorganometallic chemistry--from teaching paradigms to medicinal applications. <i>Chemical Society Reviews</i> , 2009 , 38, 391-401	58.5	840
68	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. <i>Organometallics</i> , 2009 , 28, 1165-1172	3.8	73
67	Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 916-25	8.3	156
66	From Pyrone to Thiopyrone Ligands Rendering Maltol-Derived Ruthenium(II) π -Arene Complexes That Are Anticancer Active in Vitro. <i>Organometallics</i> , 2009 , 28, 4249-4251	3.8	78
65	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds. <i>Organometallics</i> , 2009 , 28, 6260-6265	3.8	90

64	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. <i>Journal of Analytical Atomic Spectrometry</i> , 2009 , 24, 51-61	3.7	88
63	Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. <i>Anti-Cancer Drugs</i> , 2009 , 20, 97-103	2.4	193
62	5-Hydr-oxy-2-methyl-4H-pyran-4-one. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2009 , 65, o437		2
61	Antitumour metal compounds: more than theme and variations. <i>Dalton Transactions</i> , 2008 , 183-94	4.3	702
60	Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 6773-81	8.3	243
59	Resistance against novel anticancer metal compounds: differences and similarities. <i>Drug Resistance Updates</i> , 2008 , 11, 1-16	23.2	183
58	Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. <i>Inorganic Chemistry</i> , 2008 , 47, 17-9	5.1	87
57	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium-Arene Compounds. <i>Organometallics</i> , 2008 , 27, 2405-2407	3.8	171
56	Suzuki Coupling Reactions in Ether-Functionalized Ionic Liquids: The Importance of Weakly Interacting Cations. <i>Organometallics</i> , 2008 , 27, 3971-3977	3.8	73
55	High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. <i>Inorganic Chemistry</i> , 2008 , 47, 10626-33	5.1	55
54	Carbohydrate-metal complexes and their potential as anticancer agents. <i>Current Medicinal Chemistry</i> , 2008 , 15, 2574-91	4.3	137
53	Linked Metal-cluster Systems: Isolation and Characterisation of {anti-[(p-cymene)RuCl]-[12-P, P'; 1-P??-(PPh2CH2)3CMe]-[AuPt3(CO)3(PCy3)3]}(PF6)2. <i>Journal of Cluster Science</i> , 2008 , 19, 295-309	3	5
52	The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. <i>Journal of Biological Inorganic Chemistry</i> , 2008 , 13, 1149-55	3.7	210
51	In vitro anticancer activity and biologically relevant metabolism of organometallic ruthenium complexes with carbohydrate-based ligands. <i>Chemistry - A European Journal</i> , 2008 , 14, 9046-57	4.8	100
50	Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. <i>Electrophoresis</i> , 2008 , 29, 2224-32	3.6	82
49	Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. <i>Chemistry and Biodiversity</i> , 2008 , 5, 1609-14	2.5	32
48	Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication. <i>Chemistry and Biodiversity</i> , 2008 , 5, 1640-4	2.5	22
47	The hydration of chloroacetonitriles catalyzed by mono- and dinuclear Ru(II)- and Os(II)-arene complexes. <i>Chemistry and Biodiversity</i> , 2008 , 5, 2060-6	2.5	21

46	KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. <i>Chemistry and Biodiversity</i> , 2008 , 5, 2140-55	2.5	624
45	Modifying the structure of dinuclear ruthenium complexes with antitumor activity. <i>Applied Organometallic Chemistry</i> , 2008 , 22, 326-332	3.1	45
44	Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1066-76	4.2	95
43	Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 564-75	4.2	226
42	CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1060-5	4.2	87
41	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta ⁶ -p-cymene)Cl ₂ (pta)]. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 1743-8	4.2	95
40	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. <i>Journal of Inorganic Biochemistry</i> , 2008 , 102, 2136-41	4.2	57
39	Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes. <i>Tetrahedron</i> , 2008 , 64, 137-146	2.4	7
38	Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. <i>Dalton Transactions</i> , 2007 , 5065-72	4.3	119
37	Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl ₄ L(S-dmsu)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2185-93	8.3	191
36	Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. <i>Electrophoresis</i> , 2007 , 28, 2235-40	3.6	45
35	CE in anticancer metallodrug research--an update. <i>Electrophoresis</i> , 2007 , 28, 3436-46	3.6	58
34	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. <i>ChemMedChem</i> , 2007 , 2, 505-14	3.7	47
33	Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. <i>Journal of Chromatography A</i> , 2007 , 1155, 218-21	4.5	31
32	Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. <i>Molecular Pharmacology</i> , 2007 , 71, 357-65	4.3	48
31	Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. <i>Journal of Analytical Atomic Spectrometry</i> , 2007 , 22, 960-967	3.7	81
30	Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. <i>Electrophoresis</i> , 2006 , 27, 1128-35	3.6	94
29	Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. <i>Dalton Transactions</i> , 2006 , 1796-802	4.3	174

28	DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes. <i>Biochemistry</i> , 2006 , 45, 14817-25	3.2	25
27	Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. <i>Chemical Reviews</i> , 2006 , 106, 2224-48	68.1	528
26	Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions. <i>Polyhedron</i> , 2006 , 25, 1971-1978	2.7	5
25	From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). <i>Journal of Inorganic Biochemistry</i> , 2006 , 100, 891-904	4.2	806
24	Metallodrug research and analysis using capillary electrophoresis. <i>TrAC - Trends in Analytical Chemistry</i> , 2006 , 25, 868-875	14.6	44
23	Tumour-inhibiting platinum(II) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. <i>Analyst, The</i> , 2005 , 130, 1383-9	5	21
22	Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. <i>Journal of Analytical Atomic Spectrometry</i> , 2005 , 20, 856	3.7	92
21	Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2831-7	8.3	145
20	Glucose ferrocenyl-oxazolines: Coordination behavior toward [Pd(β -allyl)Cl] ₂ studied by ESI-MS. <i>Journal of Organometallic Chemistry</i> , 2005 , 690, 3301-3308	2.3	15
19	Bis- and tris-bicyclopophosphites of d-glucofuranside. Unexpected catalysis of P(III/V)-oxidation by triethylamine. <i>Tetrahedron</i> , 2005 , 61, 10943-10950	2.4	6
18	Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. <i>Analytical Biochemistry</i> , 2005 , 341, 326-33	3.1	80
17	1,1-Bis(oxazolin-2-yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(β -allyl)Cl] ₂ . <i>European Journal of Inorganic Chemistry</i> , 2005 , 2005, 1589-1600	2.3	13
16	Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. <i>Journal of Separation Science</i> , 2005 , 28, 121-7	3.4	70
15	On the Coordination Properties of New Bicyclopophosphite-Carbohydrates. <i>Monatshefte für Chemie</i> , 2005 , 136, 137-146	1.4	2
14	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. <i>Electrophoresis</i> , 2004 , 25, 1988-95	3.6	120
13	Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'Nmonophosphate O6-N7 chelation. <i>ChemBioChem</i> , 2004 , 5, 1543-9	3.8	50
12	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato- η N,O)platinum(II) as representative of novel pH sensitive anticancer platinum complexes. <i>Inorganica Chimica Acta</i> , 2004 , 357, 3237-3244	2.7	45
11	A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl ₄ (Ind) ₂] and serum proteins. <i>Journal of Inorganic Biochemistry</i> , 2004 , 98, 1135-42	4.2	74

10	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. <i>Journal of Analytical Atomic Spectrometry</i> , 2004 , 19, 46	3.7	174
9	Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges. <i>Electrophoresis</i> , 2003 , 24, 2023-37	3.6	54
8	Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. <i>Electrophoresis</i> , 2003 , 24, 2038-44	3.6	36
7	Crystallographic report: Crystal structure of 1-bromo-1'-[(2S)-N-(1-hydroxy-3-methylbutane-2-yl)]-ferroceneamide. <i>Applied Organometallic Chemistry</i> , 2003 , 17, 723-724	3.1	
6	Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes. <i>Dalton Transactions</i> , 2003 , 3098	4.3	7
5	Synthesis of ferrocenylglucose phosphonite and bisphosphinite: Pd(II) and Pt(II) complexes, Pd-catalyzed allylic alkylation. <i>Tetrahedron</i> , 2002 , 58, 8489-8492	2.4	22
4	1,1,3,3-Tetramethyl-1,3-disila-2-oxa[3]ferrocenophane: improved synthesis and new crystal structure. <i>Inorganica Chimica Acta</i> , 2002 , 328, 237-240	2.7	5
3	Novel glucose-ferrocenyl derivatives: synthesis and properties. <i>New Journal of Chemistry</i> , 2002 , 26, 671-673		28
2	Metal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and Ligands 301-330		
1	AAS, XRF, and MS Methods in Chemical Biology of Metal Complexes 63-97		5